← All trials
NCT07300956
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2026
- Primary completion
- Feb 28, 2030
- Completion date
- Jul 31, 2030
- First posted
- Dec 24, 2025
- Last posted
- Dec 24, 2025
- Enrollment
- 370
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CincinnatiLead sponsor
- University of CincinnatiSponsor investigator
- University of PennsylvaniaCollaborator
- University of KansasCollaborator
- Patient-Centered Outcomes Research InstituteCollaborator
- Stanford UniversityCollaborator
- Harvard UniversityCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.